At the Goldman Sachs 47th Annual Global Healthcare Conference held on June 8, 2026, Helen Sabzevari, President and CEO of Precigen, Inc. (PGEN), provided insights into the company's innovative approach to cell and gene therapy. Precigen operates with a unique platform that combines technology with regulatory pathways, enabling rapid development of therapies. A key feature of their approach is the AdenoVerse platform, which allows for repeat dosing of patients using specific adenovirus vectors. This technology has shown promise in clinical trials, particularly with the drug PAPZIMEOS, which has received approval for treating recurrent respiratory papillomatosis (RRP), a rare disease that has lacked effective treatment for over a century. The ability to administer this therapy repeatedly with minimal immune response is a significant advancement in the field, positioning Precigen as a leader in innovative healthcare solutions.